ArticleBMC infectious diseases2026
Clinical characteristics and prognosis of patients with Chlamydia psittaci pneumonia identified by metagenomic next-generation sequencing.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFew studies comprehensively reported the clinical characteristics, prognosis, and factors associated with severe disease in patients with confirmed Chlamydia psittaci pneumonia identified by metagenomic next-generation sequencing (mNGS).
methodsThis retrospective study included 63 patients with Chlamydia psittaci pneumonia diagnosed by mNGS. The clinical characteristics and prognosis were analyzed. Cox regression was used to identified factors associated with severe cases.
resultsA total of 63 patients were confirmed with detected Chlamydia psittaci DNA by mNGS in the bronchoalveolar lavage fluid or blood. A total of 16 (25.4%) patients had severe disease. The overall in-hospital mortality was 4.7% (3/63), with a rate of 18.7% (3/16) in the severe group. 90.4% (57/63) of patients were older than 50 years. 21 (33.3%) patients had poultry/bird exposure. The most common symptoms included fever (100%), cough (63.5%) and fatigue (63.5%). All patients showed lung consolidation (100%) on chest CT, with air bronchograms (96.8%) and pleural effusion (41.3%). In the multivariable Cox regression, the levels of hs-CRP (P = 0.003), creatinine (P = 0.002), and presence of bilateral lung infection (P = 0.003) were independent factors associated with severe pneumonia.
conclusionPsittacosis pneumonia predominantly affects middle-aged and elderly adults. Elevated levels of hs-CRP and creatinine, the presence of bilateral lung involvement associated with progression to severe disease. Psittacosis-induced severe pneumonia is associated with high mortality. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.